TY - JOUR

T1 - Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria

T2 - A double blind randomized placebo-controlled crossover trial

AU - Eickhoff, Mie K.

AU - Olsen, Flemming J.

AU - Frimodt-Møller, Marie

AU - Diaz, Lars J.

AU - Faber, Jens

AU - Jensen, Magnus T.

AU - Rossing, Peter

AU - Persson, Frederik

PY - 2020

Y1 - 2020

N2 - Aims: Sodium glucose transport inhibitors (SGLT2i) can reduce risk of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and existing cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac function in people with T2D and albuminuria. Methods: A secondary analysis of a double-blind, randomized, cross-over study of 12 weeks treatment with dapagliflozin 10 mg versus placebo. Myocardial function was assessed by echocardiography and biomarkers of cardiac risk were measured. An exploratory diastolic composite of echocardiographic variables was computed. Results: Of the 36 participants completing the study 89% were male, mean age 64 ± 8 years, diabetes duration 16.4 ± 4.7 years and HbA1c 73 ± 15 mmol/mol (8.9 ± 1.4%), 30.6% had former cardiovascular events and 32% had macroalbuminuria. Mean left ventricular ejection fraction (LVEF) was 55.4% after placebo and 54.3% after dapagliflozin (p = 0.15), global longitudinal strain −16.1 vs. −15.9, (p = 0.64), E/e′ 7.6 vs. 7.6 (p = 0.082), and tissue Doppler velocity e′ 10.0 vs. 10.6 (p = 0.05). The composite score showed diastolic function improvement of 19.8% (p = 0.021). No other significant changes were observed. Conclusions: Dapagliflozin may have minor effects on diastolic function in people with T2D, albuminuria and preserved LVEF.

AB - Aims: Sodium glucose transport inhibitors (SGLT2i) can reduce risk of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and existing cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac function in people with T2D and albuminuria. Methods: A secondary analysis of a double-blind, randomized, cross-over study of 12 weeks treatment with dapagliflozin 10 mg versus placebo. Myocardial function was assessed by echocardiography and biomarkers of cardiac risk were measured. An exploratory diastolic composite of echocardiographic variables was computed. Results: Of the 36 participants completing the study 89% were male, mean age 64 ± 8 years, diabetes duration 16.4 ± 4.7 years and HbA1c 73 ± 15 mmol/mol (8.9 ± 1.4%), 30.6% had former cardiovascular events and 32% had macroalbuminuria. Mean left ventricular ejection fraction (LVEF) was 55.4% after placebo and 54.3% after dapagliflozin (p = 0.15), global longitudinal strain −16.1 vs. −15.9, (p = 0.64), E/e′ 7.6 vs. 7.6 (p = 0.082), and tissue Doppler velocity e′ 10.0 vs. 10.6 (p = 0.05). The composite score showed diastolic function improvement of 19.8% (p = 0.021). No other significant changes were observed. Conclusions: Dapagliflozin may have minor effects on diastolic function in people with T2D, albuminuria and preserved LVEF.

KW - Albuminuria

KW - Biomarkers

KW - Cardiovascular disease

KW - Echocardiography

KW - SGLT2 inhibitor

KW - Type 2 diabetes

U2 - 10.1016/j.jdiacomp.2020.107590

DO - 10.1016/j.jdiacomp.2020.107590

M3 - Journal article

C2 - 32340841

AN - SCOPUS:85083727904

VL - 34

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 7

M1 - 107590

ER -